» Articles » PMID: 34123837

NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the and Mutational Status

Abstract

NOTCH1 mutations and deregulated signal have been commonly found in chronic lymphocytic leukemia (CLL) patients. Whereas the impact of mutations on clinical course of CLL has been widely studied, the prognostic role of NOTCH1 activation in CLL remains to be defined. Here, we analyzed the activation of NOTCH1/NOTCH2 (ICN1/ICN2) and the expression of JAGGED1 (JAG1) in 163 CLL patients and evaluated their impact on TTFT (Time To First Treatment) and OS (Overall Survival). NOTCH1 activation (ICN1+) was found in 120/163 (73.6%) patients. Among them, 63 (52.5%) were mutated (ICN1+/mutated) and 57 (47.5%) were wild type (ICN1+/WT). ICN1+ patients had a significant reduction of TTFT compared to ICN1-negative (ICN1-). In the absence of mutations, we found that the ICN1+/WT group had a significantly reduced TTFT compared to ICN1- patients. The analysis of mutational status showed that the distribution of the mutated/unmutated pattern was similar in ICN1+/WT and ICN1- patients. Additionally, TTFT was significantly reduced in ICN1+/ICN2+ and ICN1+/JAG1+ patients compared to ICN1-/ICN2- and ICN1-/JAG1- groups. Our data revealed for the first time that activation is a negative prognosticator in CLL and is not correlated to and mutational status. Activation of NOTCH2 and JAGGED1 expression might also influence clinical outcomes in this group, indicating the need for further dedicated studies. The evaluation of different NOTCH network components might represent a new approach to refine CLL risk stratification.

Citing Articles

Nanotechnology Advances in the Detection and Treatment of Lymphoid Malignancies.

Adamo F, De Falco F, Dorillo E, Sorcini D, Stella A, Esposito A Int J Mol Sci. 2024; 25(17).

PMID: 39273202 PMC: 11395233. DOI: 10.3390/ijms25179253.


CAD204520 Targets PEST Domain Mutations in Lymphoproliferative Disorders.

Pagliaro L, Cerretani E, Vento F, Montanaro A, Moron Dalla Tor L, Simoncini E Int J Mol Sci. 2024; 25(2).

PMID: 38255842 PMC: 10815907. DOI: 10.3390/ijms25020766.


-mutated chronic lymphocytic leukemia displays high endoplasmic reticulum stress response with druggable potential.

Barcelos E, Rompietti C, Adamo F, Dorillo E, De Falco F, Del Papa B Front Oncol. 2023; 13:1218989.

PMID: 37817771 PMC: 10561002. DOI: 10.3389/fonc.2023.1218989.


GSK3β is a critical, druggable component of the network regulating the active NOTCH1 protein and cell viability in CLL.

De Falco F, Rompietti C, Sorcini D, Esposito A, Scialdone A, Baldoni S Cell Death Dis. 2022; 13(9):755.

PMID: 36050315 PMC: 9436923. DOI: 10.1038/s41419-022-05178-w.


Cyclosporine A therapy of chronic lymphoblastic leukemia-related pancytopenia: A case report.

Wang M, Meng R, Gao Y, Huang J, Li T, Mao C Clin Case Rep. 2022; 10(3):e05538.

PMID: 35310307 PMC: 8908086. DOI: 10.1002/ccr3.5538.

References
1.
Baldoni S, Del Papa B, Dorillo E, Aureli P, De Falco F, Rompietti C . Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia. Int J Cancer. 2018; 143(4):958-970. PMC: 6055653. DOI: 10.1002/ijc.31355. View

2.
Kohlhaas V, Blakemore S, Al-Maarri M, Nickel N, Pal M, Roth A . Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. Blood. 2021; 137(5):646-660. DOI: 10.1182/blood.2020005734. View

3.
Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F . Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2011; 119(2):521-9. PMC: 3257017. DOI: 10.1182/blood-2011-09-379966. View

4.
Di Ianni M, Baldoni S, Rosati E, Ciurnelli R, Cavalli L, Martelli M . A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol. 2009; 146(6):689-91. DOI: 10.1111/j.1365-2141.2009.07816.x. View

5.
Arruga F, Bracciama V, Vitale N, Vaisitti T, Gizzi K, Yeomans A . Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. Leukemia. 2019; 34(2):462-477. DOI: 10.1038/s41375-019-0571-0. View